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Bone marrow hematopoietic stem cells (HSCs) are
crucial to maintain lifelong production of all blood
cells. Although HSCs divide infrequently, it is thought
that the entire HSC pool turns over every few weeks,
suggesting that HSCs regularly enter and exit cell
cycle. Here, we combine flow cytometry with label-re-
taining assays (BrdU and histone H2B-GFP) to iden-
tify a population of dormant mouse HSCs (d-HSCs)
within the linSca1+cKit+CD150+CD48CD34 popu-
lation. Computational modeling suggests that
d-HSCs divide about every 145 days, or five times per
lifetime. d-HSCs harbor the vast majority of multiline-
age long-term self-renewal activity. While they form
a silent reservoir of the most potent HSCs during ho-
meostasis, they are efficiently activated to self-renew
in response to bone marrow injury or G-CSF stimula-
tion. After re-establishment of homeostasis, acti-
vated HSCs return to dormancy, suggesting that
HSCs are not stochastically entering the cell cycle
but reversibly switch from dormancy to self-renewal
under conditions of hematopoietic stress.
INTRODUCTION
Due to the presence of multipotent stem cells, regenerating
tissues such as the skin, gut, and hematopoietic system undergo
life-long self-renewal and have the capacity to generate
terminally differentiated cell types of each lineage. Although it
is generally assumed that most immature adult stem cells divide1118 Cell 135, 1118–1129, December 12, 2008 ª2008 Elsevier Inc.infrequently and are predominantly quiescent (Arai and Suda,
2007; Orford and Scadden, 2008), recent reports raise the pos-
sibility that dormancy is either not a typical feature of somatic
stem cells or that it may depend on the stem cell type (Barker
et al., 2007; Kiel et al., 2007). However, one needs to consider
that, although definitive in vivo functional stem cell assays are
available for mammary and skin epithelial SCs as well as for
HSCs, such assays are still lacking for most other stem cell
types. Quiescence has been postulated to prevent stem cell
exhaustion (Orford and Scadden, 2008) and is thought to help
protect stem cells from acquiring mutations leading to their ma-
lignant transformation to putative cancer stem cells (Lobo et al.,
2007; Park and Gerson, 2005; Wang and Dick, 2005). The mouse
hematopoietic stem cell (HSC) is probably the most well charac-
terized adult stem cell, both phenotypically and functionally. Pre-
vious studies have proposed that HSC activity is enriched in the
quiescent cell fraction of the bone marrow (BM) (Passegue et al.,
2005; Punzel and Ho, 2001; Spangrude and Johnson, 1990). In
addition, resistance of HSCs to antiproliferative chemotherapeu-
tic agents such as fluorouracil (5-FU) or hydroxyurea is thought
to be due to their relative quiescence (Arai and Suda, 2007;
Lerner and Harrison, 1990; Venezia et al., 2004). However,
in vivo studies in the mouse using long-term incorporation of
5-bromo-2-deoxyuridine (BrdU) have challenged the existence
of long-term quiescent HSCs (Bradford et al., 1997; Cheshier
et al., 1999; Kiel et al., 2007). In these studies, the doubling
time of individual HSCs was estimated to be between 17.8 and
30 days with the entire HSC pool turning over every 57 days.
Moreover, these studies suggested that HSCs are a rather
homogenous infrequently dividing pool of cells that regularly
but asynchronously enter the cell cycle, thus excluding the exis-
tence of a dormant HSC population (Cheshier et al., 1999; Kiel
et al., 2007). In contrast, we report here the identification of
a highly dormant HSC (d-HSC) population that harbors the vast
majority of stem cell activity as shown by serial transplantation.
Although these d-HSCs divide only five times per lifetime during
homeostasis, they are rapidly and efficiently activated by G-CSF
stimulation or in response to BM injury. Interestingly, after the
blood system is repaired, activated HSCs return to dormancy,
Figure 1. LSK Cells Comprise Five Major Subpopulations
(A) Using six-color FACS, LinnegSca1+CD117+ (LSK) BM can be subdivided
into three populations based on differential expression of CD150 and CD48
(A, B, and C). The CD150+48 (A) subset can be further divided into CD34
(29.7% ± 6.3%) and CD34+ (68% ± 6%) subsets. The CD150+48+ (B) subset
is almost exclusively CD34+135, and the CD15048+ (C) subset can be
divided into CD135 (66% ± 6%) and CD135+ (34.3% ± 6%) subsets. Percent-
ages on FACS histograms are from a typical experiment. Percentages in the
text are mean ± SD of six to ten mice.
(B) The most quiescent LSK subset is the CD34150+48135 population.
Based on their relative reported reconstitution activities (reviewed in Wilson
et al., 2007) together with surface phenotype, abundance, and their relative
cell-cycle status, the five subsets described in 1A have been placed in a puta-
tive hierarchy. G0 (icKi67
, 2N DNA content), G1 (icKi67
+, 2N DNA content),
and S + G2/M (icKi67
+, > 2N DNA content). Data are mean ± SD of 6–14
6-week-old mice. HSC, hematopoietic stem cell; MPP, multipotent progenitor.
Student’s t test was performed comparing the HSC subset with each of
the other subsets in 1B for both %G0 and %S + G2/M, and in all cases,
p < 0.02. In comparing each subset with its neighboring subset, p values
were all < 0.02 with the exception of those marked #, which were not signifi-
cantly different.suggesting that HSCs reversibly switch between dormancy
and self-renewal at the interface between homeostasis and
repair.
RESULTS
Very Low Cycling Activity of CD34negLSKCD150+CD48
Cells
As ‘‘proof of principle’’ that mouse HSCs are bona fide adult
stem cells, several investigators have succeeded in performing
single-cell repopulation assays using BM subsets isolated by
flow cytometry (Camargo et al., 2006; Dykstra et al., 2007;
Wagers et al., 2002). Recently, Kiel et al. reported that 47% of in-
dividually transplanted LinSca1+c-kit+ (LSK) CD150+48 cells
generated long-term multilineage reconstitution (Kiel et al.,
2005). Previously, Nakauchi and colleagues showed that about
21% of single CD34negLSK cells had repopulation activity, while,
importantly, CD34+LSK cells showed multipotent progenitor
(MPP) but no significant HSC activity (Ema et al., 2005; Osawa
et al., 1996). In order to identify a putatively further enriched
HSC population, the percentage of CD34neg cells within the
LSKCD150+48 population was determined and found to be
29.7% ± 6.3%, suggesting that this CD34negLSK CD150+48
population should be very highly enriched for functional HSCs
(Figure 1A). Since cycling appears to correlate inversely with
stem cell activity (Orford and Scadden, 2008), the cell-cycle
status of this and other previously identified HSC/progenitor
populations (Wilson et al., 2007) was determined by combining
DNA content (Hoechst) with intracellular Ki67 expression (ex-
pressed in cycling cells, but not in quiescent G0 cells) (Wilson
et al., 2004). As shown in Figures 1B and S1 available online,
around 70% of the CD34negLSKCD150+48 population (hereaf-
ter, HSC), are in G0, and < 2% are actively cycling (S + G2/M
phases), thus making them the most rare and by far the most qui-
escent LSK cell type. In contrast, 7-fold more of the CD34+LSK
CD150+48 cells (MPP1) are actively cycling, and only 39%
are in G0. As expected, MPPs expressing CD48 and CD135
are highly proliferative (26% S + G2/M and 16% G0) (Figure 1B)
(Adolfsson et al., 2001; Weissman, 2000; Wilson et al., 2007).
These data suggest that the CD34negLSK CD150+48 population
as a whole is cycling the least and may, therefore, contain a
significant number of infrequently dividing or even dormant
cells.
A BrdU Label-Retaining Cell Population
Can Be Identified within Quiescent BM HSCs
The cell-cycle analysis performed above only measures the
instantaneous cell-cycle status and, thus, is not sensitive enough
to discriminate between infrequently dividing and bona fide
dormant cells. A technique often used to detect nondividing cells
in various tissues is the label-retaining assay in which DNA is la-
beled in vivo using BrdU followed by a long ‘‘chase’’ period that
reveals long-lived dormant ‘‘label-retaining cells’’ (LRC) (Arai
et al., 2004; Cotsarelis et al., 1990; Potten et al., 1978).
To visualize LRCs by flow cytometry, adult mice were labeled
with BrdU for 10–13 days followed by a BrdU-free chase for up to
306 days. Almost all cells within each LSK subset can be labeled
by BrdU after 13 days (Figure 2A). After 70 days of chase, theCell 135, 1118–1129, December 12, 2008 ª2008 Elsevier Inc. 1119
phenotype of BrdU label-retaining cells (LRCBrdU) in lineage-
negative BM was analyzed by flow cytometry. As shown in
Figure 2B, LRCBrdU showed a 7-fold enrichment of LSK cells
(top panels) compared to the non-LRC population (lower panels).
Most strikingly, a significant proportion of LRCBrdULSK cells was
CD34negCD150+48, suggesting that lineage-negative LRCBrdU
progenitors are highly enriched (about 120-fold) for cells with
an HSC phenotype. To determine the proportion of LRCs found
in each of the stem/progenitor subsets described in Figure 1B,
the percentage of LRCBrdU in each HSC/MPP population was
determined. As expected, the rapidly proliferating MPP and
common myeloid progenitor (CMP) populations show only
a very minor LRCBrdU population, whereas HSCs contained
32.7% ± 4.7% LRCBrdU, confirming the cell-cycle analysis
shown above and suggesting that, over time, this population
as a whole is by far the most quiescent among all stem/progen-
itor cell types examined (Figures 1B, 2C, and S2A). Kinetic anal-
yses with a chase period from 0 to 306 days (Figure 2D) revealed
that most populations had lost nearly all LRC activity after
70 days of chase. In contrast, the HSC population shows
strikingly different kinetics retaining > 20% LRCBrdUs between
70 and 200 days and even 5% after 306 days of chase
Figure 2. A BrdU Label-Retaining Cell Pop-
ulation Can Be Identified within the Most
Quiescent HSC BM Subset
(A) (Upper panel) Schematic diagram showing the
protocol for the BrdU LRC assay. (Lower panel)
Percentage of BrdU+ found in each of the subsets
described in Figure 1B after 13 days labeling
in vivo.
(B) FACS profiles of BrdU staining in BM subsets
after 70 days chase. Gating (from left to right) first
on BrdU+ (top row) or BrdU (bottom row) cells
and then the Linneg subset showing the relative
proportions of LSK cells. Then the CD150+48
subset and then the CD34 (HSC) or CD34+
(MPP1–4) subsets are shown. Numbers refer to
the percentages in each boxed gate.
(C) Percentage of LRCBrdU cells found after
70 days of chase in each of the stem/progenitor
subsets defined in Figure 1B. Data are mean ±
SD of eight mice.
(D) Percentage of BrdU+ in each of the five stem/
progenitor subsets defined in Figure 1B from 3 to
306 days chase. Loss of BrdU staining is slowest
in the CD34LSK150+48135 (HSC) population
(blue line). Data are mean ± SD of 4–12 mice.
(E) Mathematical modeling of the data shown in (D)
using the one-population version of the determin-
istic ordinary differential equation (ODE) model.
Under the parameter constraints used to create
this plot, the equations of this version of the model
(equation 2 in Supplemental Experimental Proce-
dures) simplify to the BrdU dilution equations
(random chromosome segregation case) used by
Kiel et al. (2007). RSS = 566.4. Blue dots, empirical
data; blue dotted line, days 1–10.
(F) Mathematical modeling of the data from (D)
showing both the one- and two-population ver-
sions of the ODE model. The RSS goodness-of-
fit statistics (566.4 for the one-population source,
dashed gray line; 51.1 for the two-population
source, solid brown line) strongly support a model
in which this HSC population comprises a highly
dormant subset of about 15% (d-HSC, red line)
and a more rapidly dividing subset (a-HSC, green
line) (85%). Blue dots, empirical data; blue dotted
line, days 1–10. pdt, predicted doubling time.
(G) Stochastic Markov process model of data from
(D). The mean of 1000 stochastic simulations of the two-population source (same parameter setting as in [F]) is plotted (black line) together with a 99% (assuming
normality) confidence interval (green dash-dotted lines). Blue dots, empirical data.
(H) Stochastic modeling of data shown in (D). The data shown are the simulated observed average of 35,000 virtual cells. The threshold number of marked
chromatids for a cell to be counted as positive is assumed to be 7, and the resulting graph is plotted in blue. Experimental data are marked as black crosses
and are all included in an envelope of ±3 chromatids for the choice of threshold. For further details to the modeling, see Supplemental Experimental Procedures.1120 Cell 135, 1118–1129, December 12, 2008 ª2008 Elsevier Inc.
(Figure 2D), raising the possibility that a long-term dormant sub-
population may exist within this HSC population.
To address this question, we first determined experimentally
that a BrdU-labeled cell must undergo around 4.5 divisions be-
fore BrdU expression becomes undetectable by flow cytometry
(Figure S2B). We then modeled the temporal dynamics of BrdU
decay (Figure 2D) with a mathematical model, assuming the
data was generated by a single population of cells with a ho-
mogenous division rate similar to a method used by Kiel et al.
(2007) (Supplemental Experimental Procedures). However, as
shown in Figure 2E, this model does not fit our experimental
data, so we extended this one-population ordinary differential
equation (ODE) model to create a two-population version
(Figure 2F). As a result, we observed a highly significant im-
provement in the goodness of fit with the two-population
ODE model (Figure 2F, brown), predicting that the
LRCBrdUCD34negLSKCD150+48 population most likely com-
prises two populations with different division kinetics: a
d-HSC (red) subset (15%) dividing approximately every
145 days and a rarely dividing ‘‘activated’’ (a-HSC, green) pop-
ulation (85%) dividing around every 36 days (Figure 2F). These
results were independently confirmed by modeling the same
data using two different stochastic approaches: one based on
a continuous time state-discrete Markov process in which con-
fidence limits (±3 SD) can be determined (Figure 2G) and the
other a Monte Carlo program that simulates individual cells
(Figure 2H) (see Supplemental Experimental Procedures). Fi-
nally, we remodeled the BrdU-LRC data set recently reported
by Kiel et al. (2007) (only three data points: days 40, 70, and
120 of chase) using our two-population ODE model. Curiously,
we found that, while this data cannot readily be described by
a single population, it can be explained with great accuracy
by our two-population model in agreement with our own more
extensive data set (van der Wath and Lio´, 2008) (Figure S4). In
summary, by modeling BrdU decay in LRC-HSCs, over time
we can reveal the presence of a dormant population that
comprises about one-seventh of the CD34negLSKCD150+48
subset dividing once every 145 days, which is equivalent to
about five divisions per C57/BL6 lifetime (Siegl-Cachedenier
et al., 2007).
LRCBrdUcKit+ Cells Can Be Visualized in the BM
Typically, localization of HSCs in the BM is assayed by injecting
purified, labeled HSCs into the circulation, followed by histolog-
ical analysis of the BM around 15 hr later (Nilsson et al., 2001;
Wilson et al., 2004). However, whether detection of HSCs using
such ‘‘homing assays’’ indeed indicates their true niche location
remains controversial (Wilson et al., 2007). Our findings that
HSCs are highly enriched in the LRC fraction permit detection
of ‘‘resident’’ dormant HSCs by immunofluorescence staining
for BrdU and cKit (CD117) in bones of mice after 170 days chase.
At this time point, the only cKit+ cells in the BM that are still BrdU+
are d-HSCs (data not shown). As shown in Figure S3,
LRCBrdU;cKit+ cells can be detected both near the endosteum
and more centrally in the BM. Importantly, LRCBrdU;cKit+ cells
are always detected as single cells, indicating that niches har-
boring dormant HSCs are very small.Functional Long-Term HSCs Are Enriched
in the LRCH2GFP Fraction of the BM
To address the functional HSC activity of the dormant popula-
tion, reconstitution experiments need to be performed.
However, since it is necessary to fix cells to detect BrdU incor-
porated into DNA, LRCBrdU cells cannot be isolated alive nor can
their functional activity be assessed. To circumvent this limita-
tion and perform functional assays on label-retaining HSCs,
we took advantage of a transgenic mouse line that expresses
the fusion protein histone H2B-green fluorescent protein
(H2B-GFP) under the control of a tetracycline-responsive regu-
latory element (Tumbar et al., 2004). To obtain hematopoietic
stem/progenitor-specific and doxycyclin-dependent expres-
sion of H2B-GFP, these mice were crossed to SCL-tTA-S2
mice (SCL-tTA) expressing the tTA-S2 transactivator from the
endogenous scl locus expressed in both early embryonic and
adult HSC/progenitor cells (Figure 3A) (Bockamp et al., 2006).
More than 80% of HSC/MPPs isolated from 6-week-old SCL-
tTA;H2B-GFP double heterozygous mice expressed GFP at
high levels (GFPbright) (Figure 3B), whereas only much lower
levels of GFP, (at least 1 log dimmer) were detected in these
subsets isolated from control H2B-GFP (Challen and Goodell,
2008) or SCL-tTA single transgenic mice, or SCL-tTA;H2B-
GFP mice that had been permanently treated with doxycyclin
(Figure 3B and data not shown). Although around 20% of these
stem and progenitor populations did not express detectable
levels of GFP, no differences were observed in the phenotype
of the GFP+ and GFP fractions in any of the BM subsets pre-
chase (Figure S3), suggesting that both populations are identical
and that the differential expression of H2B-GFP is due to posi-
tion effect variegation often observed with transgenes (Kioussis
and Festenstein, 1997).
Similar to what was observed in LRCBrdU cells, after 70 days of
chase (+ doxycyclin), LinnegGFPbright cells were highly enriched
for noncycling CD34negLSKCD150+48 HSCs (LRCH2B-GFP)
(Figure 3C). Furthermore, the proportion of LRCH2B-GFP cells
was highest (35% ± 4.8%) in the HSC population and signifi-
cantly lower in the more differentiated MPPs (Figure 3D). Kinetic
analysis of LRCH2B-GFP within the HSC population shows that the
rate of loss of LRCH2B-GFP cells over time is remarkably similar to
that observed with LRCBrdU, suggesting that both techniques are
highly equivalent (Figure 3E). This is also in agreement with re-
cently reported data showing that five divisions are required for
a H2B-GFP+ cell to be rendered undetectable by FACS (Wagh-
mare et al., 2008), consistent with what we have estimated for
the loss of BrdU label (Figure S2B).
For DNA to retain a label such as BrdU, two independent hy-
potheses have been postulated. First, it has been proposed in
the ‘‘Immortal Strand Hypothesis’’ that stem cells divide fre-
quently but, in doing so, asymmetrically recognize and retain
the ‘‘old’’ labeled mother DNA strand while the newly synthe-
sized ‘‘unlabeled’’ chromosomes are selectively distributed to
the nonstem cell daughter (Cairns, 1975; Potten et al., 1978). Al-
though some evidence for this controversial hypothesis has
been provided in several cell types, including muscle satellite
stem cells, the immortal strand segregation mechanism has re-
cently been seriously challenged for HSCs (Kiel et al., 2007;
Lansdorp, 2007; Shinin et al., 2006). Since we see highlyCell 135, 1118–1129, December 12, 2008 ª2008 Elsevier Inc. 1121
overlapping decay kinetics in HSCs labeled either with BrdU
(chromosomal labeling) or H2B-GFP (labeling of nuclear
proteins), one would need to predict for the Immortal Strand
Hypothesis to hold true—that not only chromosomes but also
the histone-2B-GFP protein would have to be asymmetrically
distributed, a rather unlikely assumption. Therefore, in the ab-
sence of any evidence that HSCs asymmetrically segregate their
chromosomes, the observed label retention must be due to
dormancy during the chase period. To confirm this experimen-
tally, we determined the cell-cycle status of LRCH2B-GFP cells
(CD34negLSK 150+48) by DNA content and Ki67 expression
after 204 days chase. As shown in Figures 3F and 6B, none
(0.2% ± 0.3%) of these cells are in S/G2/M phases (compared
to 1% in non-LRC cells of the same phenotype). Moreover,
nearly all (99% ± 0.7%) are in G0 phase compared to 83% in
Figure 3. LRCH2B-GFP HSCs Are Exclusively
in a G0 State
(A) Schematic diagram of breeding and treatment
strategy for LRC assays using SCL-tTA;H2B-GFP
transgenic mice.
(B) GFP fluorescence intensity in HSC subsets of
SCL-tTA;H2B-GFP (green), H2B-GFP (gray), and
SCL-tTA (black) mice prechase (no treatment
with doxycyline) (left). Histograms (right), percent-
age of GFP+ cells in each LSK subset. Data are
mean ± SD from three mice.
(C) Relative enrichment (270-fold) of
CD34LSKCD150+CD48 HSCs in LRCH2B-GFPs
(80 days chase) compared to non-LRCs. DNA
content of LRCH2B-GFP (top) and non-LRC (bottom)
in LSK.
(D) LRC assay after 80 days chase of SCL-
tTA;H2B-GFP mice. Results are mean ± SD from
four mice.
(E) Comparison of loss of LRC kinetics (0–240
days) in the CD34LSK150+48135 HSC subset
using the BrdU (blue) or SCL-tTA;H2B-GFP
(green) LRC assay. Data are mean ± SD of three
to eight mice per time point.
(F) DNA content (Hoechst 33342) versus Ki67
staining of LRCH2B-GFP CD34LSKCD150+CD48
(left) and non-LRC CD34150+48LSK (right) after
204 days chase. Schematic diagram to right
shows the cell-cycle phase represented by each
quadrant.
(G) qRT-PCR for CD34 expression. Results are
expressed as fold increase inCD34mRNA expres-
sion in CD34LSKCD150+CD48LSK non-LRC
compared to LRCH2B-GFP cells (after 145 or
170 days of chase). Blue squares, individual
mice; red bar, mean increase. Results are from
five individual estimations on FACS-sorted cells
from individual animals.
non-LRCs, confirming that long-term la-
bel retention in HSCs is a highly sensitive
parameter for quiescence. To address
the molecular basis of dormancy, micro-
array analysis comparing dormant
LRCH2BGFP (170 days chase) versus acti-
vated non-LRC HSCs was performed.
This analysis revealed that expression of almost all genes in-
volved in the assembly and activation of the prereplicative com-
plex were downregulated in dormant HSCs. This includes key
factors such as CDC6, CDC7, and DNA polymerase-a (Figure S5)
(Coller, 2007). These data show that LRC-HSCs have a greatly
downregulated DNA replication machinery, which is consistent
with the status of dormancy. Acquisition of CD34 cell-surface ex-
pression on adult HSCs is known to be one of the first events
concomitant with loss of HSC activity (Furness and McNagny,
2006; Matsuoka et al., 2001). Indeed, although d-HSCs showed
very little CD34 mRNA expression as expected, this gene is tran-
scriptionally upregulated >100-fold in a-HSCs (Figure 3G)
although they remain cell-surface CD34neg, consistent with the
notion that the two HSCs and MPP1 show a close linear relation-
ship (Figures 3G and 5).1122 Cell 135, 1118–1129, December 12, 2008 ª2008 Elsevier Inc.
To compare the functional HSC activity of d-HSCs (LRCH2B-GFP
HSCs) with a-HSCs (LRCneg HSCs), 50 cells of either pheno-
type were FACS sorted and transplanted into lethally irradiated
NOD/SCID/gc mice (Ito et al., 2002). Most mice reconstituted
with d-HSCs survived more than 15 weeks and contained do-
nor-derived myeloid and lymphoid (B and T) cell lineages in the
BM and blood (Figure 4A, left). In contrast, recipients trans-
planted with the same number of a-HSCs had a significantly
higher death rate after transplantation. The few that survived
did, however, show multilineage repopulation (Figure 4A, right).
To assess their long-term self-renewal capacity, 2 chimeras
were prepared 15 weeks after the primary transfer by transplant-
ing 5000 LinnegSca1+GFPbright cells isolated from either d-HSC
or a-HSC 1 chimeras as above. Strikingly, most 2 recipients
that received cells from chimeras reconstituted with a-HSCs
died (seven out of ten) within the first 4 weeks (Figure 4B, left),
and, of the three survivors, only one showed significant but
low multilineage reconstitution (Figure 4B, right). In contrast,
most secondary recipients (nine out of ten) reconstituted with
Figure 4. Functional Long-Term HSCs Are
Contained within the LRCH2B-GFP Fraction
(A) Survival of lethally irradiated NOD/SCID/gc
mice reconstituted with LRCH2B-GFP
CD34LSK150+48135 (green) or non-LRC cells
(black line or white box) after 1 transfer (left
panel). Results are from six mice per genotype.
(Lower left and right) multilineage reconstitution
from LRCH2B-GFP HSCs. T (CD4 versus CD8), B
(B220), and myeloid (CD11b versus Gr1) cells in
spleen (LRCH2B-GFP or non-LRC donors) 15 weeks
postreconstitution compared to NOD/SCID/gc
PBLs (far right).
(B) A 2 transfer. Same analysis as for 1 transfer.
Survival curves, ten mice per genotype. Analysis
15 weeks after the 2 transfer. *, no cells in donor
gate.
(C) Relative reconstitution efficiencies of
LRCH2B-GFP CD34LSK150+48135 (green cir-
cles) or non-LRC cells (open circles) 12 weeks
after 1 transfer into sublethally irradiated Rag/gc
mice. Total number of BM, spleen, and thymus
(left). Total numbers of CD45.1+ (donor) granulo-
cytes (Gran), macrophages (Mac), and B cells in
BM 13 weeks after transfer (upper right). *p < 0.02.
Results are from seven mice per genotype.
(D) Reconstitution efficiency 29 weeks after 2
transfer (as in [C]). Results from 7 (non-LRC) or
12 mice (LRCH2B-GFP). Circles or squares repre-
sent individual mice; red bar represents mean.
Survival and reconstitution summary of PBLs of
2 transfer 29 weeks postreconstitution.
LinnegSca1+GFPbright cells derived from
the d-HSC chimeras survived and showed
multilineage reconstitution (Figure 4B).
To further confirm that d-HSCs have
multilineage long-term self-renewal ca-
pacity, competitive reconstitution experi-
ments were performed. To this end, 50
LRCH2B-GFP or non-LRCs HSCs (day
213 chase) were isolated by FACS as above and transferred
into sublethally irradiated Rag2/gc recipients (Colucci et al.,
1999). As anticipated, the relative reconstitution efficiencies
were significantly different (Figure 4C). At 12 weeks after transfer,
donor-derived cells constituted 59%–95% (79% ± 13%) of PBLs
in all mice reconstituted with LRCH2B-GFP HSCs (seven out of
seven), whereas only four out of seven mice transferred with
non-LRC HSCs contained any donor cells. Although multilineage
reconstitution (lymphoid, erythroid, and myeloid) was observed
in all reconstituted mice, after the 1 transfer, LRCH2B-GFP
HSCs performed significantly better than non-LRC HSCs
(Figure 3C). To confirm that LRCH2B-GFP HSCs have greater
self-renewal potential than non-LRC HSCs, a 2 transfer was
performed. CD45.1+LinnegSca1+ donor BM was FACS sorted
from the LRCH2B-GFP HSC or non-LRC HSC 1 transfer, and a lim-
iting number of 2850 cells were transferred as above. Similar to
the 1 transfer, at 29 weeks posttransfer, 12 out of 12 mice had
reconstituted with LRCH2B-GFP HSCs, while only three out of
seven mice transferred with non-LRC HSCs had any donor cellsCell 135, 1118–1129, December 12, 2008 ª2008 Elsevier Inc. 1123
in the PBLs (Figure 4D). In addition, multilineage differentiation
was exclusively observed in mice reconstituted with
LRCH2B-GFP HSCs (Figure 4D). Taken together, these two serial
BM transfer experiments show that the vast majority of long-
term multilineage reconstitution potential is found within the
dormant LRCH2B-GFP HSC subset in the BM (Figure 5).
Dormant HSCs Can Be Activated by G-CSF or by Injury
Signals Such as 5-FU or BrdU
Due to their apparent dormancy, it is unlikely that d-HSCs signif-
icantly contribute to the steady-state maintenance of homeosta-
sis requiring the daily generation of millions of blood cells. In
several stem cell-controlled tissues, it is assumed that stem cells
may be activated in response to injury signals (Blanpain et al.,
2007). To test whether d-HSCs are activated in response to my-
eloid depression, LRCBrdU mice were treated with the chemo-
therapeutic agent 5-FU after a 70 day chase, and the number
of d-HSCs (LRCBrdU HSCs) was determined 10 days later. Since
it has been previously shown that HSCs themselves are resistant
to 5-FU (Lerner and Harrison, 1990; Venezia et al., 2004), the
retention or loss of BrdU should provide a readout whether
d-HSCs remain dormant or cycle after injury. As illustrated in
Figure 6A, the majority of d-HSCs become BrdU (left) or H2B-
GFP (right) negative after 5-FU treatment presumably by diluting
out the label due to cellular proliferation. Indeed, 2 days after
commencing 5-FU treatment, 38% ± 17% of LRCGFP HSCs
have exited the G0 phase of the cell cycle and are actively cycling
(G1/S/G2/M), demonstrating their recruitment from the dormant
into an activated state (Figure 6B). Similarly, treatment of mice
with the cytokine G-CSF, known to mobilize HSCs (Lapidot
and Petit, 2002), also causes dormant HSCs to proliferate effi-
ciently, as the majority of the LRCBrdU HSCs lose the BrdU label
(Figure 6A). Importantly, no LRCBrdU or LRCGFP HSCs are found
in the spleen or liver before or after either 5-FU or G-CSF treat-
ment, although non-LRC HSCs are clearly present after injury
or mobilization (Figure 6C and data not shown). This is consistent
with the finding that G-CSF priming followed by treatment
with cylcophosphamide, which kills dividing cells, eliminates
most HSCs (Wright et al., 2001). Thus, G-CSF not only promotes
mobilization but also activates dormant HSCs.
Figure 5. Model Showing a Dormant HSC on Top of the Adult Hema-
topoietic Hierarchy
Injury signals (green arrow; Inj, injury) lead to reversible HSC activation (red
arrow; Hom, homeostasis).1124 Cell 135, 1118–1129, December 12, 2008 ª2008 Elsevier Inc.To test whether injury-activated, self-renewing HSCs are able
to return to a dormant status, unmanipulated mice were treated
with 5-FU for 6 days to induce injury-mediated proliferation of
HSCs (Randall and Weissman, 1997) followed by a 6 day
BrdU-labeling period and, finally, a 70 day chase period (Fig-
ure 6D). Using this scheme, almost the entire HSC pool was
BrdU labeled prechase (>98%) (Figure 6E), and after 70 days
without BrdU, about 30% remained as LRCBrdU, which is strik-
ingly similar to what has been observed without the initial 5-FU
treatment (Figures 2C, 2D, and 6A). Since the labeling of HSCs
after 5-FU was virtually complete, the BrdU label can be consid-
ered as a ‘‘lineage tracer,’’ suggesting that the LRCBrdU HSCs
retained after the chase are most likely directly derived from
these proliferating HSCs or possibly even progenitors. These
data support the concept that the injury-induced proliferation
of d-HSCs is reversible and that at least some of these cells
return to dormancy after homeostasis has been re-established
(Figure 5).
Finally, the question arises of why only 13 days of BrdU treat-
ment of adult mice is so efficient in labeling the DNA of dormant
HSCs that divide only once every 21 weeks. One possibility
could be that young mice still expand their HSC number by sym-
metric division and, thus, become labeled in the presence of
BrdU. However, this is unlikely to be the case since HSCs of
mice as old as 16 months could still be efficiently labeled by
10 days of BrdU treatment (Figure 7A). Alternatively, long-term
BrdU treatment could be toxic to some hematopoietic cell types
and, thus, may induce a positive feedback loop similar to that
generated by 5-FU-induced myeloid depression (Randall and
Weissman, 1997). Consistent with this hypothesis, BrdU has pre-
viously been reported to be toxic for various cell types, including
neuronal stem/progenitor and mature hematopoietic cells, both
in vitro and in vivo (Caldwell et al., 2005; Mitchell et al., 1983;
Morstyn et al., 1985). Strikingly, 24 hr after commencing BrdU
treatment, HSCs efficiently exit G0 and enter the S + G2/M
phases of the cell cycle, strongly suggesting activation and
cell-cycle entry of HSCs (Figure 7B). Similarly, although BrdU
uptake of HSCs is very slow between 2 and 24 hr (Figure 7C),
it increases significantly during longer labeling periods (2 to
10 days) (Figure 7C, arrow), reaching levels comparable to the
faster-dividing MPP populations. This correlates with a decrease
of erythroid and myeloid cells in mice treated with BrdU
(Figure 7D) (Morstyn et al., 1985), suggesting that this toxic effect
of BrdU causes an injury response similar but weaker than 5-FU,
leading to activation and proliferation of HSCs. Thus, previous
studies using long-term BrdU uptake kinetics have missed the
d-HSC population since all HSCs are induced to proliferate
due to BrdU toxicity on differentiated blood cells, and, therefore,
no dormant HSCs remain in this setting (Figure 7C) (Bradford
et al., 1997; Cheshier et al., 1999). Finally, the efficient cell-cycle
entry of HSCs as early as 24 hr after BrdU treatment (Figure 7B)
also explains why the vast majority of dormant HSCs in the adult
mouse can be labeled after only 13 days (Figure 2B), thus clari-
fying why label-retaining assays using BrdU are possible at all.
Collectively, our data suggest that HSCs with the greatest multi-
lineage reconstitution potential remain dormant during homeo-
stasis. This silent pool of HSCs, which would comprise about
600 HSCs per mouse (Wilson et al., 2007), is efficiently induced
to self-renew and differentiate in response to cytokines such
as G-CSF or BM stress (5-FU and BrdU). After repair, these cells
re-establish a dormant pool of highly functional HSCs.
DISCUSSION
In this study, we identify a highly dormant population of func-
tional HSCs within the linSca1+cKit+CD150+CD48CD34
population of mouse BM. They express only low levels of
CD34 mRNA, have downregulated their prereplicative com-
plexes, are exclusively in the G0 phase of cell cycle, and, during
homeostasis, they divide about every 145 days. These d-HSCs
were identified by two long-term label-retaining approaches
using either BrdU labeling or a H2B-GFP transgene. Although
a previous study also identified BrdULRC with an HSC phenotype,
the number was significantly lower compared to our studies
(>10-fold). Thus, it was concluded that HSCs do not retain
BrdU and are not highly quiescent or dormant (Kiel et al.,
2007). The increased detection sensitivity of BrdULRC in our
study is likely due to two major improvements. First, we find
most BrdULRC in a more restricted LSKCD150+48 subset (the
Figure 6. Dormant HSCs Can Be Activated
by 5-FU or G-CSF
(A) Percentage of LRCBrDU in untreated mice
(blue), mice treated with 5-FU (dark gray), or
mice treated with G-CSF (pale gray) in stem/
progenitor subsets defined in Figure 1B after
70 days chase. Results are mean ± SD of six to
eight mice.
(B) DNA content (Hoechst) versus Ki67 expression
of LRCGFP (CD34LSKCD150+CD48) cells
(204 days chase) in untreated mice (left) or
2 days post 5-FU treatment (three right panels).
Schematic diagram (below right) shows the cell-
cycle phase represented by each quadrant. Histo-
grams (below left) show percentage mean ± SD of
cells in the G0 (left) or S + G2/M (right) phases of
cell cycle. Data are from the FACS plots above
(three mice per group). p < 0.05.
(C) FACS profiles show gating of linneg BM (top two
rows) and spleen (lower two rows), used to define
LRCBrdU (CD34LSKCD150+CD48) in untreated
(UT) or 10 days after 5-FU treatment (10 days
5-FU), after 70 days chase. Histograms (right)
show percentage of LRCBrdU.
(D) Scheme depicting initial injury (5-FU) followed
by BrdU labeling followed by chase.
(E) Percentage of BrdU+ in subsets defined in
Figure 1B at day 12 (see [D]) prechase. Results
are mean ± SD of four mice.
(F) Percentage of LRCBrdU in subsets defined in
Figure 1B at day 92 (after 70 day chase). Results
are mean ± SD of four mice.
29% CD34neg fraction) (Figure 1A). Sec-
ond, we have directly analyzed the cells
ex vivo using seven-parameter FACS
rather than staining previously sorted
HSCs for BrdU mostly on glass slides.
Thus, our ex vivo analysis is more sensi-
tive and may also exclude the putative loss of ‘‘BrdU-injured’’
HSCs during the stressful laser-mediated cell-sorting process.
Moreover, we have mathematically remodeled the original Kiel
et al. LRC data (only three time points) and found that their
data would also strongly favor the presence of a dormant popu-
lation within the LSKCD48CD150+ population (Figure S4) (van
der Wath and Lio´, 2008), which is in agreement with our more
extensive study that functionally identifies the high self-renewal
capacity of d-HSCs.
Our identification of a dormant population with high stem cell
activity in adult mice extends recent studies showing that
HSCs undergo a sudden switch from a predominantly prolifera-
tive fetal liver and postnatal HSC compartment to a more quies-
cent one 4 weeks after birth (Bowie et al., 2006, 2007). This
supports the concept that maturation of adult HSCs is linked
to their cell-cycle behavior, thus suggesting that many mature
adult HSCs exit the cell cycle upon reaching adulthood. Our
data show that the vast majority of long-term HSC activity is
retained in < 1000 dormant stem cells that divide only about
five times during the remaining lifespan of the organism. During
ontogeny and early postnatal development, the blood systemCell 135, 1118–1129, December 12, 2008 ª2008 Elsevier Inc. 1125
is essential and potentially limiting in supporting the rapid growth
of the organism and continuous expansion of all hematopoietic
lineages. However, upon reaching homeostasis in adulthood,
the hematopoietic system now needs only to be maintained.
Although billions of cells must still be produced daily to replace
short-lived cell types such as erythrocytes or neutrophils, this
requires significantly less cellular proliferation compared to
what is needed during the expansion and growth phases of em-
bryonic and postnatal development. Taken together, our data
and those from Bowie et al. support the hypothesis that, by hav-
ing the most active HSCs enter a dormant state, the expansion
mode is switched off. This process apparently occurs at various
levels. First, it has previously been shown that functional HSCs
have a slow metabolism (Suda et al., 2005). Second, they appear
to express low levels of ribosomal RNA as they are found in the
Pyronin Y low fraction (Gothot et al., 1997; Passegue et al.,
2005). In addition, our microarray data suggest that the DNA
replication machinery, including ORC and MCM complexes,
DNA polymerases, and associated enzymes involved in the gen-
eration of the prereplicative complex, is also downregulated in
dormant HSCs. Thus, adult HSCs are not simply resting but
are in a deeply inactive state involving reduced metabolism, ribo-
somal biogenesis, and DNA replication, all consistent with dor-
mancy. Since despite their dormancy, these cells exhibit the
highest self-renewal potential of all blood cells, the organism
must protect them from any mutations that may unleash their
potential in an uncontrolled manner that may, in turn, promote
their stepwise transformation into leukemic stem cells (Lobo
et al., 2007; Wang and Dick, 2005). As one reason for acquisition
of mutations is certainly due to replication errors, the observed S
phase silencing of d-HSCs would protect them from this.
Figure 7. BrdU-Induced Hematopoietic
Toxicity Induces an Injury Response in
Dormant HSCs
(A) BrdU uptake in CD34LSKCD150+CD48 BM
after 10 days treatment in mice of indicated
ages. Results are mean ± SD of four mice per
age group.
(B) Percentage of S + G2/M (blue) or G0 (red) in
CD34LSK150+48135 HSCs before and after
BrdU treatment at times indicated. Results are
mean ± SD of four to eight mice for each time
point.
(C) BrdU uptake of stem/progenitor subsets
defined in Figure 1B during continuous labeling
from 2 to 240 hr. (Red) CD34LSK150+48135
HSCs. Results are mean ± SD of six to eight
mice for each time point. The red arrow marks
the rapid increase of BrdU incorporation after
hour 24.
(D) Kinetics of loss of BM myeloid, erythroid, and
lymphoid cells post BrdU treatment. Results are
mean ± SD of four mice per time point.
In addition, stem cells are thought to be
compartmentalized in areas difficult to
reach by infectious agents or toxic and
mutagenic compounds (Trumpp and
Wiestler, 2008). Since three-dimensional reconstruction of im-
munohistochemical sections is currently not possible, it remains
unclear whether dormant HSCs found in the middle of the BM are
close to underlying bone or whether cells may also be located in
niches distinct from the endosteum. Importantly, dormant cells
were almost exclusively detected as single cells, suggesting
that dormant niches may only house individual HSCs.
Although stem/progenitor cells have also been reported to be
localized near the microvasculature in the so-called vascular
niche more or less distant from the endosteum, most genetic
data support the hypothesis that functional stem cells need to in-
teract with osteoblasts located at the endosteal niche (Kiel et al.,
2005; Wilson and Trumpp, 2006; Zhang et al., 2003). Our data in-
dicating that some dormant HSCs are also found close to the
endosteum would support the hypothesis that the endosteal
niche may contribute to maintenance of the most potent
HSCs. Moreover, many signaling molecules present at the
HSC-niche synapse (Graf and Trumpp, 2007; Wilson and
Trumpp, 2006) have been suggested to maintain HSCs in a qui-
escent state. This includes Ang1-Tie2, TPO-cMPL, and SCF-cKit
signaling. Mutations in any of these genes lead to increased HSC
cycling followed by loss of stem cell activity probably due to ex-
haustion (Qian et al., 2007; Thoren et al., 2008; Yoshihara et al.,
2007). Thus, HSC dormancy is also an important strategy for the
adult organism to prevent stem cell exhaustion (Orford and
Scadden, 2008). Although adult stem cells have long-term self-
renewal capacity, this seems not to be unlimited. For example,
serial HSC transplantation is only possible for about six rounds,
showing that, in contrast to tumor cells, the capacity of adult
stem cells to self-renew is limited (Allsopp et al., 2003; Harrison
and Astle, 1982). Therefore, a potential function of an endosteal1126 Cell 135, 1118–1129, December 12, 2008 ª2008 Elsevier Inc.
niche would be to keep the most potent HSCs dormant during
homeostasis in order to preserve their self-renewal capacity
and prevent stem cell exhaustion. The role of a vascular niche
remains more uncertain, but an interesting possibility would be
that activated and actively self-renewing HSCs destined to
differentiate could be present in this type of niche, for example,
where more oxygen is available to support the increased metab-
olism and cell-cycle activity of these stem cells (Graf and
Trumpp, 2007).
Due to their extremely rare production of progeny, dormant
HSCs are unlikely to significantly contribute to the daily mainte-
nance of adult hematopoiesis. Instead, our data show that dor-
mant HSCs can be robustly activated to proliferate in response
to injury cues, thus suggesting that dormant cells serve as a re-
serve pool of stem cells only recruited in situations of emergen-
cies such as BM injury. This ‘‘awakening’’ process appears to be
dose dependent since weak myeloid suppression induced by
a single dose of the hematotoxic compound BrdU results in
only partial reactivation of dormant HSCs. In contrast, virtually
all HSCs can be recruited into the cell cycle in response to severe
myeloid depletion induced by 5-FU. Most interestingly, a dor-
mant HSC pool is restored after the lost cells have been replaced
and homeostasis is re-established. This phenomenon provides
evidence that activated HSCs can return to a dormant HSC sta-
tus. Reversibility between dormancy and activation has long
been hypothesized for cells at the top of the stem/progenitor hi-
erarchy, although little in vivo data has been provided in higher
organisms (Quesenberry, 2006). Nevertheless, when germline
stem cells in the Drosophila ovary are eliminated, progenitors
can move into the artificially emptied niche and reacquire stem
cell properties (Xie and Spradling, 2000). Thus, it is possible
that other somatic stem cells in adult tissues also show some
degree of reversibility. Our data now suggest that reversibility
may be a physiological function of activated a-HSCs at the inter-
face between injury repair and re-establishment of homeostasis.
Whether this reversibility, like in invertebrates, involves exit and
reentry of cells into niches is a likely scenario although techni-
cally difficult to address. Another key question is the identifica-
tion of endogenous signals that activate dormant HSCs in
response to myeloid injury. These signals remain unknown,
although our data show that treatment with G-CSF and IFN-a
(M. Essers and A.T., unpublished data) can efficiently activate
dormant HSCs in vivo. Activation of dormant stem cells may
also be important in malignancy. It is thought that some leukemic
stem cells such as chronic myeloid leukemia (CML) stem cells
are also in a state of quiescence/dormancy, which is a possible
mechanism for their resistance to antiproliferative chemotherapy
(Aguirre-Ghiso, 2007; Trumpp and Wiestler, 2008). Pretreatment
with stem cell-activating molecules such as G-CSF should make
dormant cancer stem cells (CSC) sensitive to antiproliferative
chemotherapy. Indeed, quiescent CML-SCs can be eliminated
in vitro by imatinib only after priming with G-CSF (Jorgensen
et al., 2006).
In summary, in the healthy adult, we show that HSCs with the
highest self-renewal capacity are kept in a dormant state to
preserve their activity. However, their stem cell capacity can
be reversibly released in emergency situations, leading to effi-
cient and rapid repair of blood lineages. These findings alsohave relevance for diseases, including cancer, in which chronic
injury may lead to a constant activation of stem cells, resulting
in the accumulation of mutations and generation of CSCs. Future
identification of signals and niches of dormant and activated
stem cells may have a major impact not only on the understand-
ing of tissue repair but also on the cellular basis of chronic




The transgenic mouse line that expresses the fusion protein histone H2B-
green fluorescent protein (H2B-GFP) under the control of a tetracycline-
responsive regulatory element (Tumbar et al., 2004) was purchased from
Jackson Laboratories (Bar Harbor, ME). To obtain hematopoietic stem/
progenitor-specific and doxycyclin-dependent expression of H2B-GFP, these
mice were crossed to SCL-tTA-S2 mice (SCL-tTA) expressing the tTA-S2
transactivator from the endogenous scl locus (hereafter, called SCL-
tTA;H2B-GFP) (Bockamp et al., 2006).
BrdU Treatment and Label-Retaining Assays
In vivo 5-bromodeoxy-uridine (BrdU, Sigma) labeling (up to 13 days) was
performed as previously described (Wilson et al., 2004). For the LRCH2B-GFP
assay, SCL-tTA;H2B-GFP mice were maintained on water containing
2 mg/ml doxycyline hydrate (Sigma) in 5% glucose for the entire chase period.
For 5-FU treatment, mice were injected with a single dose (150 mg/g i.p.) of
5-fluorouracil (Sigma) 2 or 10 days prior to analysis of LRCs. G-CSF was given
daily for 5 days prior to analysis (5 mg/mouse i.p.).
BrdU Detection and Cell-Cycle Analysis
BrdU staining was quantitated by flow cytometry (Wilson et al., 2004) by com-
bining surface staining to define each BM subset with intracellular staining us-
ing the BrdU-APC staining kit following the manufacturer’s instructions (BD
Biosciences). Cell-cycle analysis combined with eight-color surface staining
to define BM subsets was performed as previously described (Wilson et al.,
2004) using Ki67-FITC (BD Biosciences) and DAPI or Hoechst 33342 (Molec-
ular Probes).
BM Reconstitution Studies
LRCH2B-GFP CD34LSK150+48 and non-LRC CD34LSK150+48 BM
(CD45.1+) were FACS sorted. Fifty cells of each type were transferred i.v.
together with 106 Sca1-depleted rescue BM (same genotype as host) into
lethally (NOD/SCID/gc) or sublethally irradiated (325 rads) (CD45.2 RAG/gc)
hosts. Chimerism was assessed in PBLs by staining for CD45.1 (donor exper-
imental) and CD45.2 (rescue BM and host) at 4, 8, and 12 weeks posttransfer.
For the 2 transfers, CD45.2+LinSca1+ cells were sorted from BM isolated
from either group of the 1 chimeras at 12 or 15 weeks and transferred as
above. PBLs were analyzed for reconstitution efficiency lineage contribution
6, 12, and 29 weeks posttransfer.
Quantitative Real-Time PCR
Expression levels of CD34 mRNA were determined in RNA isolated from
LRCH2B-GFP CD34LSK150+48 and non-LRC CD34LSK150+48 BM sorted
as described above (145 days chase). The PicoPure RNA kit (Arcturus, Menlo
Park, CA) was utilized for RNA isolation. This RNA was amplified and single-
stranded cDNA was prepared using the Ovation RNA Amplification System
V2 (NuGEN, San Carlos, CA). Quantitative PCR for CD34 mRNA was
performed on a Light Cycler (Roche). Average value and standard deviation
was calculated on five replicate measurements.
Microarray Amplification and Hybridization Methods
Total RNA was isolated from FACS-sorted LRCH2B-GFP CD34LSKCD150+48
and non-LRC CD34LSKCD150+48 BM (170 days chase) as described
above. Biotin labeling of cRNA was performed utilizing the Enzo BioArrayCell 135, 1118–1129, December 12, 2008 ª2008 Elsevier Inc. 1127
High Yield RNA Transcript labeling kit (Enzo Biotech, Farmington, CT). This
biotinylated RNA was fragmented and hybridized to Affymetrix MOE430 v.2
chips (Affymetrix, Santa Clara, CA) as per the manufacturer’s protocol. Both
raw image (.dat) and intensity (.cel) files were generated utilizing the Affymetrix
Gene Chip Operating Software (GCOS).
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures
and six figures and can be found with this article at http://www.cell.com/
supplemental/S0092-8674(08)01386-X.
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